

1 **TITLE PAGE**

2 **Full-length title:**

3 **Sequential appearance and isolation of a SARS-CoV-2 recombinant between two major**
4 **SARS-CoV-2 variants in a chronically infected immunocompromised patient**

5 **Short title (for the running head):**

6 **SARS-CoV-2 recombinations between variants during chronic infection**

7 **Author list: Emilie BUREL^{1,2}‡, Philippe COLSON^{1,2,3}‡, Jean-Christophe LAGIER^{1,2,3},**

8 **Anthony LEVASSEUR^{1,2}, Marielle BEDOTTO¹, Philippe LAVRARD^{1,2,3}, Pierre-**

9 **Edouard FOURNIER^{1,2,4}, Bernard LA SCOLA^{1,2,3}*, Didier RAOULT^{1,2}***

10 **Affiliations:** ¹ IHU Méditerranée Infection, 19-21 boulevard Jean Moulin, 13005 Marseille,
11 France; ² Aix-Marseille Univ., Institut de Recherche pour le Développement (IRD), Microbes
12 Evolution Phylogeny and Infections (MEPHI), 27 boulevard Jean Moulin, 13005 Marseille,
13 France; ³ Assistance Publique-Hôpitaux de Marseille (AP-HM), 264 rue Saint-Pierre, 13005
14 Marseille, France; ⁴ Aix-Marseille Univ., Institut de Recherche pour le Développement (IRD),
15 Vecteurs – Infections Tropicales et Méditerranéennes (VITROME), 27 boulevard Jean
16 Moulin, 13005 Marseille, France.

17 ‡ Contributed equally

18 * **Corresponding author:** Didier Raoult, IHU Méditerranée Infection, 19-21 boulevard Jean

19 Moulin, 13005 Marseille, France. Tel.: +33 413 732 401, Fax: +33 413 732 402; email:

20 didier.raoult@gmail.com; Bernard La Scola, IHU Méditerranée Infection, 19-21 boulevard

21 Jean Moulin, 13005 Marseille, France. Tel.: +33 413 732 401, Fax: +33 413 732 402; email:

22 bernard.la-scola@univ-amu.fr.

23 **Key words:** SARS-CoV-2; variant; recombination; chronic infection; immunosuppression

24 **Word counts:** abstract, 212; text, 2,353

25 **Figures:** 3; **Tables:** 2; **References:** 48; **Supplementary Material:** Supplementary Methods,

26 **Results, Figure S1, and Table S1**

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47

ABSTRACT

Genetic recombination is a major evolutionary mechanism among RNA viruses, and it is common in coronaviruses, including those infecting humans. A few SARS-CoV-2 recombinants have been reported to date whose genome harbored combinations of mutations from different mutants or variants, but a single patient's sample was analyzed, and the virus was not isolated. Here, we re-report the gradual creation of a hybrid genome of B.1.160 and Alpha variants in a lymphoma patient chronically infected for 14 months, and we isolated the recombinant virus. The hybrid genome was obtained by next-generation sequencing, and recombination sites were confirmed by PCR. This consisted of a parental B.1.160 backbone interspersed with two fragments, including the spike gene, from an Alpha variant. Analysis of seven sequential samples from the patient decoded the recombination steps, including the initial infection with a B.1.160 variant, then a concurrent infection with this variant and an Alpha variant, the generation of hybrid genomes, and eventually the emergence of a predominant recombinant virus isolated at the end of the patient's follow-up. This case exemplifies the recombination process of SARS-CoV-2 in real life, and it calls for intensifying genomic surveillance in patients coinfecting with different SARS-CoV-2 variants, and more generally with several RNA viruses, as this may lead to the creation of new viruses.

48

TEXT

49

50 INTRODUCTION

51 A major evolutionary mechanism of RNA viruses is genetic recombination [1,2].
52 Recombinations are extremely common in coronaviruses and have been implicated in the
53 emergence of several genotypes, including endemic human coronaviruses [3-6]. The in-
54 volvement of genetic recombination in the origin of SARS-CoV-2 is also suspected [7].
55 Regarding SARS-CoV-2, coinfection in the same patient with distinct variants has been
56 reported [8-14]. In addition, several studies have described or suspected genetic recom-
57 binations for this virus [10,13-14,15-25]. However, most of these recombinants relied solely
58 on the coexistence of signature mutations of different SARS-CoV-2 variants in ge-nomes
59 obtained from a single patient's sample, and they were not isolated in culture. Since January
60 2020, our laboratory has screened more than one million respiratory specimens for SARS-
61 CoV-2 infection by real-time reverse transcription-PCR (qPCR) without interruption or
62 limited capacity including for all patients sampled in our institute and in the Marseille public
63 hospitals [26,27]. This has provided us with sequential samples from multiple patients, and
64 enabled us to detect reinfections, and prolonged or even chronic infections in severely
65 immunocompromised patients [28-30]. Here, we re-port the gradual creation of a recombinant
66 SARS-CoV-2 involving two variants in a lymphoma patient chronically infected over a period
67 of 14 months, and the isolation of the recombinant virus in culture.

68

69 RESULTS

70 *Chronic SARS-CoV-2-infection in a severely immunocompromised patient*

71 An immunocompromised adult patient had an uncontrolled SARS-CoV-2 infection for
72 14 months until death (Supplementary Material: Supplementary Methods and Results). This
73 patient had been previously diagnosed with mixed Hodgkin and follicular lymphoma. In

74 2020, the patient developed severe SARS-CoV-2-associated pneumonia as diagnosed
75 virologically by qPCR. Despite clinical improvement, viral clearance did not occur as SARS-
76 CoV-2 RNA remained detectable by qPCR on most nasopharyngeal samples collected until
77 patient's death. qPCR was negative at Month 5 of diagnosis but positive when re-tested at
78 Month 7, and then only transiently negative for ≤ 3 days.

79 *Evidence of hybrids of variants*

80 After 14 months of infection, we identified a virus whose genome was a hybrid of two
81 known variants, B.1.160 [according to Pangolin lineage ([https://cov-](https://cov-lineages.org/resources/pangolin.html)
82 [lineages.org/resources/pangolin.html](https://cov-lineages.org/resources/pangolin.html)) [31]] [a.k.a. Nextstrain clade (<https://nextstrain.org/>)
83 [32] 20A.EU2, or Marseille-4 [27]] and Alpha [according to the WHO denomination
84 (<https://www.who.int/fr/activities/tracking-SARS-CoV-2-variants>) (a.k.a. 20I or B.1.1.7)]
85 (Figure 1; Figure 2).

86 This hybrid genome was obtained from the respiratory samples by next-generation
87 sequencing, as previously described [27]. In addition, the hybrid virus was isolated in culture,
88 as previously described [33]. The hybrid genome sequence consisted of a B.1.160 variant
89 matrix, of which two regions, the first one being located at the 5' tip of the genome and
90 containing synonymous mutation C913U and the second one spanning from positions 17,109-
91 18,877 to positions 25,710-27,972, were replaced by those of an Alpha variant (Figure 1;
92 Figure 2; Supplementary Material: Figure S1). All eight signature mutations of the Alpha
93 variant were detected in the spike gene in the absence of the S477N mutation that is a
94 signature of the B.1.160 variant. Nucleotide diversity at the 35 positions harboring signature
95 mutations of the Alpha or B.1.160 variants was low [mean (\pm standard deviation) value of
96 $3.1 \pm 6.8\%$] (Figure 2; Supplementary Material: Figure S1), indicating that the hybrid content
97 of the genome was not explained by a co-infection by the two variants or by contamination.
98 These findings indicated that this mosaic genome was the result of recombinations between
99 parental genomes of the B.1.160 and Alpha variants.

100 *Genome of the initial virus*

101 By analyzing the sequential samples available from this patient, we were able to
102 determine that he was first infected with the B.1.160 variant, which was epidemic at the time
103 of diagnosis of his infection during summer 2020. This variant predominated in our region
104 from August 2020 until January 2021 and was replaced by the Alpha variant that emerged in
105 December 2020 [27]. SARS-CoV-2 could not be isolated retrospectively from this sample,
106 but its genome was typical of a B.1.160 variant and displayed no significant nucleotide
107 diversity (mean, $0.2\pm 0.5\%$). It was classified by phylogeny as a B.1.160 variant (Figure 3).
108 Unfortunately, although SARS-CoV-2 qPCR was still positive in another laboratory at Month
109 4 post-diagnosis, the sample was unavailable, and we were not able to verify that only this
110 virus had persisted and that there was no co-infection with an Alpha variant at this time. Thus,
111 we did not obtain the genome and an isolate of the Alpha variant. The closest sample in time
112 to the initial one dated from Month 8, and it already demonstrated a mosaicism between
113 genomes of B.1.160 and Alpha variants (Figure 1, Figure 2).

114 *Steps in creation of the recombinant*

115 We used three procedures to characterize the different recombination steps by
116 analyzing seven sequential respiratory samples collected from the patient (Tables 1, 2). First,
117 sequencing from the respiratory samples of the viral genomes; second, sequencing from the
118 respiratory samples of PCR products overlapping the putative recombination sites; and third,
119 viral culture with sequencing of the genomes of the isolates. These approaches allowed us to
120 evidence that several viruses and recombinant forms had coexisted in the sequential samples,
121 as signature mutations of the two variants were co-detected at multiple positions, with a
122 nucleotide diversity that reached high levels and evolved over time (Figure 2; Supplementary
123 Material: Supplementary Results and Figure S1). We observed an evolution towards the
124 genome sequence of the recombinant virus that predominated at the end of the patient's
125 follow-up, following recombination events at three sites between parental genomes of B.1.160

126 and Alpha variants, with a low level of nucleotide diversity observed at that time at the
127 positions harboring signature mutations of these variants.

128

129 **DISCUSSION**

130 We highlight here in an immunocompromised lymphoma patient who received several
131 treatments the presence after 14 months of infection of a hybrid virus of two known variants,
132 B.1.160 and Alpha, which successively predominated in our region during the period during
133 which this patient was followed-up [35, 27]. The first evidence of a hybrid genome was
134 obtained 8 months after the diagnosis of infection by the B.1.160 variant, and the absence of
135 available samples covering this period did not allow us to date the superinfection by the
136 Alpha variant. The signature mutations of the Alpha variant observed in the hybrid genomes
137 between 8 and 14 months cannot have occurred randomly considering their number and
138 distribution along the genome and their majority presence, and their location indicates
139 recombinations in three regions. In addition, genomic analyses carried out for sequential
140 respiratory samples and viral cultures demonstrate the successive presence of several viruses
141 with hybrid genomes, one of them having established itself in this patient and remaining the
142 one that continued circulating until his death.

143 We believe that this observation, which sheds light on the recombination mechanism
144 of RNA viruses, is significant, and to our knowledge this is the first one describing, through
145 the analysis of sequential samples over more than a year, the creation of a re-combinant
146 SARS-CoV-2 and the isolation of the recombinant virus in culture. Sixteen interlineage
147 recombinants between the Alpha variant and non-Alpha viruses were reported in 2021 in the
148 UK, of 279,000 genomes analyzed [8]. In addition, 1,175 (0.2%) putative recombinant
149 genomes were identified among 537,360 genomes, and it was reported that up to 5% of
150 SARS-CoV-2 that circulated in the USA and UK might be recombinants [18]. Moreover, the
151 number of cases of detection of recombinant genomes is growing [10,13-14,15-25]. Recently,

152 coronaviruses have been reported to be able to integrate se-quences putatively from insects
153 [36]. Such natural mosaicism in these viruses make it possible to understand the emergence
154 of RNA viruses and should lead to a strengthening of genomic surveillance in patients
155 presenting with coinfections by several RNA viruses, as is observed in patients infected with
156 several respiratory viruses including SARS-CoV-2, endemic human coronaviruses, influenza
157 viruses, or rhinoviruses [37]. Such infectious episodes could perhaps lead to the creation of
158 new emerging viruses, as has been for instance reported for enteroviruses of humans and great
159 apes [38].

160

161 **MATERIALS AND METHODS**

162 ***SARS-CoV-2 genome sequencing***

163 SARS-CoV-2 genome sequencing was performed as previously described. Briefly,
164 viral RNA was extracted from 200 µL of nasopharyngeal swab fluid using the EZ1 Virus
165 Mini kit v2.0 on an EZ1 Advanced XL instrument (Qiagen, Courtaboeuf, France) or using the
166 MagMax Viral/Pathogen Nucleic Acid Isolation kit on the KingFisher Flex system (Thermo
167 Fisher Scientific, Waltham, MA, United States), following the manufacturer's instructions.
168 SARS-CoV-2 genome sequences were obtained by next-generation sequencing with various
169 procedures with the Illumina COVIDSeq protocol on a NovaSeq 6000 instrument (Illumina
170 Inc.), or by multiplex PCR with ARTIC nCoV-2019 V3 Panel primers (IDT, Coralville, IA,
171 USA) combined with the Oxford Nanopore technology (ONT) on a GridION instrument
172 (Oxford Nanopore Technologies Ltd., Oxford, United Kingdom), as previously described
173 [27,14]. After its extraction, viral RNA was reverse-transcribed according to the COVIDSeq
174 protocol (Illumina Inc.) or using the LunaScript RT SuperMix kit (New England Biolabs)
175 when performing next-generation sequencing with the Nanopore technology, following the
176 manufacturer's recommendations.

177 ***Genome analysis***

178 After using the Nanopore technology combined with the ARTIC protocol, fastq files
179 were processed using the ARTIC field bioinformatics pipeline (ARTIC-nCoV-
180 bioinformaticsSOP-v1.1.0; <https://github.com/artic-network/fieldbioinformatics>), as
181 previously described [27,14]. NGS reads were basecalled using Guppy (4.0.14) and aligned to
182 the genome of the Wuhan-Hu-1 isolate, GenBank accession No. MN908947.3, using
183 minimap2 (v2.17-r941) (<https://github.com/lh3/minimap2>) [39]. The ARTIC tool align_trim
184 was used to softmask primers from read alignment and cap sequencing depth at a maximum
185 of 400-fold coverage. Consensus-level variant candidates were identified using a threshold of
186 70% and the Medaka (v.0.11.5) workflow developed by ARTIC ([https://github.com/artic-](https://github.com/artic-network/artic-ncov2019)
187 [network/artic-ncov2019](https://github.com/artic-network/artic-ncov2019)). From the unique sequence obtained with the ARTIC-Nanopore
188 technology, a sorted bam file was loaded on the CLC Genomics workbench v7 software and a
189 tsv file was then exported. NovaSeq reads were basecalled using the Dragen Bcl Convert
190 pipeline (v3.9.3; [https://emea.support.illumina.com/sequencing/sequencing_software/bcl-](https://emea.support.illumina.com/sequencing/sequencing_software/bcl-convert.html)
191 [convert.html](https://emea.support.illumina.com/sequencing/sequencing_software/bcl-convert.html) (Illumina Inc.)). Mapping was carried out on the Wuhan-Hu-1 isolate genome
192 with the bwa-mem2 tool (v2.2.1; <https://github.com/bwa-mem2/bwa-mem2>) and was cleaned
193 with Samtools (v1.13; <https://www.htslib.org/>) [40]. Variant calling was performed with
194 freebayes (v1.3.5; <https://github.com/freebayes/freebayes>) [41] and consensus genomes were
195 built with Bcftools (v1.13; <https://samtools.github.io/bcftools/bcftools.html>). Freebayes
196 results were filtered with a threshold of 70% for the majority nucleotide. A tsv file was
197 generated using an in-house Python script. The clade was designated at the consensus level
198 with the Nextclade online tool (<https://clades.nextstrain.org/>) [42,32] and an in-house Python
199 script allowed detection of variants and hybrids of variants. At the sub-consensus level,
200 variant frequencies compared to the Wuhan-Hu-1 isolate genome were calculated from tsv
201 files. Nucleotide diversity at genomic positions was calculated using the Microsoft Excel
202 software (<https://www.microsoft.com/en-us/microsoft-365/excel>) with an in-house built file.
203 It corresponded to the proportion of sequence reads that do not harbor the consensus

204 (majority) nucleotide. Genome sequences obtained in the present study were submitted to the
205 GISAID sequence database (<https://www.gisaid.org/>) [34] (see Supplementary Material:
206 Supplementary Table S1).

207 ***Generation of additional sequence reads***

208 Sequencing of reverse-transcription-PCR-targeted regions: Extraction of the RNA
209 samples was carried out using the EZ1 Virus kit with the EZ1 Advanced XL instrument
210 (Qiagen) following the manufacturer's recommendations. PCR amplification of the 3 regions
211 was amplified in a 25 μ L total volume using the SuperScript III One-Step RT-PCR Kit
212 (Invitrogen, Carlsbad, CA, USA), using primer concentrations of 200 nM per reaction. PCR
213 were performed with following conditions: 50°C for 25 min, 95°C for 2 min, then 40 cycles
214 including 15 s at 95°C, 45 s at 60°C, and 2 min at 68°C. Sequences of PCR primers are
215 provided in the Supplementary Material. Amplicons were sequenced with Nanopore
216 technology on a GridION instrument (Oxford Nanopore Technologies Ltd.), following
217 manufacturer's instructions. Fastq files were processed as described above. Continuous reads
218 overlapping signature mutations of distinct variants were filtered using SAMtools (v1.13;
219 <https://github.com/samtools/>) [40] combined with an in-house awk script. Reads were then
220 filtered according to variant-specific nucleotide patterns using SAMtools combined with an
221 in-house awk script. Groups of reads with same patterns of mutations were then visualized
222 using the IGV software (<https://software.broadinstitute.org/software/igv/>) [43].

223 Metagenomic sequencing: Nucleic acid extraction was performed with the EZ1 Virus
224 kit with the EZ1 Advanced XL instrument (Qiagen) following the manufacturer's
225 recommendations, using 200 μ L of sample and eluting in 60 μ L of elution buffer. Reverse
226 transcription was performed with all 60 μ L of this solution using the TaqMan Reverse
227 Transcription Reagent kit (Applied-Biosystems, Foster City, CA, USA), according to the
228 manufacturer's protocol under the following conditions: 10 min at 25°C, 30 min at 48°C, and
229 5 min at 95°C. Then, 300 μ L of obtained cDNA was transferred in a 1.5 mL Eppendorf

230 LoBind tube (Eppendorf, Le Pecq, France). Second DNA strand was synthesized by adding a
231 mix of 24 µL of Klenow Fragment DNA polymerase (New England Biolabs, Beverly, MA,
232 USA), 66 µL of nuclease-free water, 45 µL of NEB Buffer 2 (New England Biolabs), and 15
233 µL of dNTPs working solution produced with 10 µL of each dNTP at a 100 mM
234 concentration, and 60 µL of nuclease-free water (New England Biolabs). This mix was kept at
235 37°C for one hour. A purification step consisted in adding 450 µL of magnetic CleanNGS
236 beads for a 1:1 volume ratio (CleanNA, Waddinxveen, the Netherlands) then incubating for 5
237 min in a magnetic support, and washing with 1,000 µL of ethanol at 70%, before elution of
238 beads in 50 µL of Tris EDTA 1X with centrifugation for 10 min at 300 rpm at room
239 temperature. Subsequently, DNA library was prepared with the DNA ligation sequencing kit
240 SQK-LSK109 (Oxford Nanopore Technologies Ltd.), and next-generation sequencing was
241 performed with the Nanopore technology on a PromethION instrument (Oxford Nanopore
242 Technologies Ltd.). Each sample was sequenced on a different PromethION Flow cell R10.4
243 (Oxford Nanopore Technologies Ltd.).

244 ***Phylogenetic analysis on whole and partial genomes***

245 Phylogenetic analyses were performed separately for the twelve genome sequences
246 and the twelve spike gene sequences obtained from the nasopharyngeal samples or the culture
247 supernatants. Sequences were aligned using MAFFT v.7 [44] with their 20 most similar hits
248 identified with the BLAST tool [45] among SARS-CoV-2 genomes from our database that
249 contains sequences obtained from clinical samples collected between February 2020 and
250 February 2022 [27,14]. Phylogeny reconstruction was performed using the IQ-TREE software
251 with the GTR Model and 1,000 ultrafast bootstrap repetitions (<http://www.iqtree.org>) [46],
252 and trees were visualized with iTOL (Interactive Tree Of Life) (<https://itol.embl.de/>) [47] and
253 MEGA X (v10.2.6; <https://www.megasoftware.net/>) [47] softwares.

254 ***Virus culture isolation***

255 Culture isolation was performed on Vero E6 cells, as previously described [33].

256

257

258 **Acknowledgments**

259 We are thankful to Ludivine Brechard, Claudia Andrieu, Raphael Tola, Jeremy
260 Delerce for their technical help; to Sophie Amrane and Justine Raclot for their help with the
261 clinical management; and to the medical biology laboratory Alphabio, hôpital Européen,
262 Marseille, France, for providing some results of SARS-CoV-2 qPCR testing.

263 **Author contributions**

264 P.C., B.L.S., and D.R. conceived the project. E.B., P.C., J.-C.L., A.L., M.B., and P.L.
265 provided materials or performed analyses. E.B., P.C., J.-C.L., A.L., M.B., P.-E.F., B.L.S., and
266 D.R. analyzed the data. E.B., P.C., P.-E.F., B.L.S, and D.R. drafted the paper. All authors
267 participated in the discussion and interpretation of the results. All authors edited and
268 proofread the final manuscript. All authors have read and agreed to the published version of
269 the manuscript.

270 **Funding**

271 This work was supported by the French Government under the “Investments for the
272 Future” program managed by the National Agency for Research (ANR) (Méditerranée-
273 Infection 10-IAHU-03), by the Région Provence Alpes Côte d’Azur and European funding
274 FEDER PRIMMI (Fonds Européen de Développement Régional-Plateformes de Recherche et
275 d’Innovation Mutualisées Méditerranée Infection) (FEDER PA 0000320 PRIMMI), and by
276 the French Ministry of Higher Education, Research and Innovation (ministère de
277 l’Enseignement supérieur, de la Recherche et de l’Innovation) and the French Ministry of
278 Solidarity and Health (Ministère des Solidarités et de la Santé).

279 **Data availability**

280 The dataset generated and analyzed during the current study is available in the
281 GISAID sequence database (<https://www.gisaid.org/>) [34].

282 **Conflicts of interest**

283 The authors have no conflicts of interest to declare relative to the present study. Didier
284 Raoult was a consultant for the Hitachi High-Technologies Corporation, Tokyo, Japan from
285 2018 to 2020. He is a scientific board member of the Eurofins company and a founder of
286 a microbial culture company (Culture Top). Funding sources had no role in the design and
287 con-duct of the study, the collection, management, analysis, and interpretation of the data, and
288 the preparation, review, or approval of the manuscript.

289 **Ethics**

290 This study has been approved by the ethics committee of University Hospital Institute
291 (IHU) Méditerranée Infection (No. 2022-008). Access to the patients' biological and registry
292 data issued from the hospital information system was approved by the data protection
293 committee of Assistance Publique-Hôpitaux de Marseille (APHM) and was recorded in the
294 European General Data Protection Regulation registry under number RGPD/APHM 2019-73.

295

296

297

298

REFERENCES

299

- 300 1. Xiao, Y.; Rouzine, IM.; Bianco S.; et al. RNA Recombination Enhances Adaptability
301 and Is Required for Virus Spread and Virulence. *Cell Host Microbe*. 2017, 22, 420. doi:
302 10.1016/j.chom.2017.08.006.
- 303 2. Bentley, K.; Evans, D.J. Mechanisms and consequences of positive-strand RNA virus
304 recombination. *J Gen Virol*. 2018, 99, 1345-1356. doi: 10.1099/jgv.0.001142.
- 305 3. Lai, MMC. Recombination in large RNA viruses: Coronaviruses. *Semin Virol*. 1996, 7,
306 381-388.
- 307 4. Zhang, Y.; Li, J.; Xiao, Y.; et al. Genotype shift in human coronavirus OC43 and
308 emergence of a novel genotype by natural recombination. *J Infect*. 2015, 70, 641-50.
- 309 5. So, RTY.; Chu, DKW.; Miguel, E.; et al. Diversity of Dromedary Camel Coronavirus
310 HKU23 in African Camels Revealed Multiple Recombination Events among Closely
311 Related Betacoronaviruses of the Subgenus Embecovirus. *J Virol*. 2019, 93, e01236-19.
312 doi: 10.1128/JVI.01236-19.
- 313 6. Gribble, J.; Stevens, L.J.; Agostini, M.L.; et al. The coronavirus proofreading
314 exoribonuclease mediates extensive viral recombination. *PLoS Pathog*. 2021, 17,
315 e1009226. doi: 10.1371/journal.ppat.1009226.
- 316 7. Zhu, Z.; Meng, K.; Meng, G. Genomic recombination events may reveal the evolution
317 of coronavirus and the origin of SARS-CoV-2. *Sci Rep*. 2020, 10, 21617. doi:
318 10.1038/s41598-020-78703-6.
- 319 8. Jackson, B.; Boni, MF.; Bull, MJ.; et al. Generation and transmission of interlineage
320 recombinants in the SARS-CoV-2 pandemic. *Cell*. 2021, 184, 5179-5188.e8.
- 321 9. Francisco, R.D.S. Jr.; Benites, L.F.; Lamarca, A.P.; et al. Pervasive transmission of
322 E484K and emergence of VUI-NP13L with evidence of SARS-CoV-2 co-infection

- 323 events by two different lineages in Rio Grande do Sul, Brazil. *Virus Res.* 2021, 296,
324 198345. doi: 10.1016/j.virusres.2021.198345.
- 325 10. Taghizadeh, P.; Salehi, S.; Heshmati, A.; et al. Study on SARS-CoV-2 strains in Iran
326 reveals potential contribution of co-infection with and recombination between different
327 strains to the emergence of new strains. *Virology.* 2021, 562, 63-73. doi:
328 10.1016/j.virol.2021.06.004.
- 329 11. Rockett, J.D.; Gall, M.; Sim, E.M.; et al. Co-infection with SARS-CoV-2 Omicron and
330 Delta Variants revealed by genomic surveillance. *medRxiv* 2022, 2022.02.13.22270755;
331 doi: <https://doi.org/10.1101/2022.02.13.22270755>.
- 332 12. Musso, N.; Maugeri, J.G.; Bongiorno, D.; et al. SARS-CoV-2's high rate of genetic
333 mutation under immune selective pressure: from oropharyngeal B.1.1.7 to
334 intrapulmonary B.1.533 in a post-vaccine patient. *Int J Infect Dis.* 2022, S1201-
335 9712(22)00123-0. doi: 10.1016/j.ijid.2022.02.044.
- 336 13. He, Y.; Ma, W.; Dang, S.; et al. Possible recombination between two variants of
337 concern in a COVID-19 patient. *Emerg Microbes Infect.* 2022, 11, 552-555. doi:
338 10.1080/22221751.2022.2032375.
- 339 14. Colson, P.; Fournier, P.E.; Delerce, J.; et al. Culture and identification of a
340 “Deltamicron” SARS-CoV-2 in a three cases cluster in southern France *medRxiv* 2022,
341 2022.03.03.22271812; doi: <https://doi.org/10.1101/2022.03.03.22271812>
- 342 15. Yi, H. 2019 Novel Coronavirus Is Undergoing Active Recombination. *Clin Infect Dis.*
343 2020, 71, 884-887. doi: 10.1093/cid/ciaa219.
- 344 16. Yeh, T.Y.; Contreras, G.P. Emerging viral mutants in Australia suggest RNA
345 recombination event in the SARS-CoV-2 genome. *Med J Aust.* 2020, 213, 44-44.e1.
346 doi: 10.5694/mja2.50657. Epub 2020 Jun 7. PMID: 32506536; PMCID: PMC7300921.

- 347 17. Gallaher, W.R. A palindromic RNA sequence as a common breakpoint contributor to
348 copy-choice recombination in SARS-COV-2. *Arch Virol.* 2020, 165, 2341-2348. doi:
349 10.1007/s00705-020-04750-z.
- 350 18. VanInsberghe, D.; Neish, A.S.; Lowen, A.C.; Koelle, K. Recombinant SARS-CoV-2
351 genomes are currently circulating at low levels. *bioRxiv.* 2021 Mar
352 15:2020.08.05.238386. doi: 10.1101/2020.08.05.238386.
- 353 19. Haddad, D.; John, S.E.; Mohammad, A.; et al. SARS-CoV-2: Possible recombination
354 and emergence of potentially more virulent strains. *PLoS One.* 2021, 16, e0251368.
- 355 20. Varabyou, A.; Pockrandt, C.; Salzberg, S.L.; Perteau, M. Rapid detection of inter-clade
356 recombination in SARS-CoV-2 with Bolotie. *Genetics.* 2021, 218, iyab074. doi:
357 10.1093/genetics/iyab074.
- 358 21. Leary, S.; Gaudieri, S.; Parker, M.D.; et al. Generation of a novel SARS-CoV-2 sub-
359 genomic RNA due to the R203K/G204R variant in nucleocapsid: homologous
360 recombination has potential to change SARS-CoV-2 at both protein and RNA level.
361 *bioRxiv.* 2021 Aug 6:2020.04.10.029454. doi: 10.1101/2020.04.10.029454. Update in:
362 *Pathog Immun.* 2021 Aug 20;6(2):27-49.
- 363 22. Lohrasbi-Nejad, A. Detection of homologous recombination events in SARS-CoV-2.
364 *Biotechnol Lett.* 2022, 17, 1–16. doi: 10.1007/s10529-021-03218-7.
- 365 23. Kreier, F. Deltacron: the story of the variant that wasn't. *Nature.* 2022, 602, 19.
- 366 24. Ignatieva, A.; Hein, J.; Jenkins, P.A. Ongoing Recombination in SARS-CoV-2
367 Revealed through Genealogical Reconstruction. *Mol Biol Evol.* 2022, 39, msac028. doi:
368 10.1093/molbev/msac028.
- 369 25. Sekizuka, T.; Itokawa, K.; Saito, M.; et al. Genome Recombination between Delta and
370 Alpha Variants of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
371 *Jpn J Infect Dis.* 2022 Feb 28. doi: 10.7883/yoken.JJID.2021.844.

- 372 26. Million, M.; Lagier, J.C.; Tissot-Dupont, H.; et al. Early combination therapy with
373 hydroxychloroquine and azithromycin reduces mortality in 10,429 COVID-19
374 outpatients. *Rev Cardiovasc Med.* 2021, 22, 1063-1072. doi: 10.31083/j.rcm2203116.
- 375 27. Colson, P.; Fournier, PE.; Chaudet, H.; et al. Analysis of SARS-CoV-2 Variants From
376 24,181 Patients Exemplifies the Role of Globalization and Zoonosis in Pandemics.
377 *Front Microbiol.* 2022, 12, 786233. doi: 10.3389/fmicb.2021.786233.
- 378 28. Brouqui, P.; Colson, P.; Melenotte, C.; et al. COVID-19 re-infection. *Eur J Clin Invest.*
379 2021, 51, e13537. doi: 10.1111/eci.13537.
- 380 29. Drancourt, M.; Cortaredona, S.; Melenotte, C.; et al. SARS-CoV-2 Persistent Viral
381 Shedding in the Context of Hydroxychloroquine-Azithromycin Treatment. *Viruses.*
382 2021, 13, 890. doi: 10.3390/v13050890.
- 383 30. Colson, P.; Devaux, C.A.; Lagier, J.C.; Gautret, P.; Raoult, D. A Possible Role of
384 Remdesivir and Plasma Therapy in the Selective Sweep and Emergence of New SARS-
385 CoV-2 Variants. *J Clin Med.* 2021, 10, 3276. doi: 10.3390/jcm10153276.
- 386 31. Rambaut, A.; Holmes, E.C.; O'Toole, A.; et al. A dynamic nomenclature proposal for
387 SARS-CoV-2 lineages to assist genomic epidemiology. *Nat Microbiol.* 2020, 5, 1403-
388 1407. doi: 10.1038/s41564-020-0770-5.
- 389 32. Aksamentov, I.; Roemer, C.; Hodcroft, E.B.; Neher, R.A. Nextclade: clade assignment,
390 mutation calling and quality control for viral genomes. Zenodo 2021,
391 <https://doi.org/10.5281/zenodo.5607694>.
- 392 33. La Scola, B.; Le Bideau, M.; Andreani, J.; et al. Viral RNA load as determined by cell
393 culture as a management tool for discharge of SARS-CoV-2 patients from infectious
394 disease wards. *Eur J Clin Microbiol Infect Dis.* 2020, 39, 1059-1061.
- 395 34. Alm, E.; Broberg, EK.; Connor, T.; et al. Geographical and temporal distribution of
396 SARS-CoV-2 clades in the WHO European Region, January to June 2020. *Euro*
397 *Surveill.* 2020, 25, 2001410.

- 398 35. Fournier, P.E.; Colson, P.; Levasseur, A.; et al. Emergence and outcomes of the SARS-
399 CoV-2 'Marseille-4' variant. *Int J Infect Dis.* 2021, 106, 228-236.
- 400 36. Tengs, T.; Delwiche, C.F.; Monceyron Jonassen, C. A genetic element in the SARS-
401 CoV-2 genome is shared with multiple insect species. *J Gen Virol.* 2021, 102, 001551.
- 402 37. Le Glass, E.; Hoang, V.T.; Boschi, C.; et al. Incidence and Outcome of Coinfections
403 with SARS-CoV-2 and Rhinovirus. *Viruses.* 2021, 13, 2528.
- 404 38. Amona, I.; Medkour, H.; Akiana, J.; et al. Enteroviruses from Humans and Great Apes
405 in the Republic of Congo: Recombination within Enterovirus C Serotypes.
406 *Microorganisms.* 2020, 8, 1779.
- 407 39. Li, H. Minimap2: pairwise alignment for nucleotide sequences. *Bioinformatics.* 2018,
408 34, 3094-3100. doi:10.1093/bioinformatics/bty191
- 409 40. Hadfield, J.; Megill, C.; Bell, S.M.; Huddleston, J.; Potter, B.; Callender, C. Nextstrain:
410 real-time tracking of pathogen evolution. *Bioinformatics.* 2018, 34, 4121–4123.
- 411 41. Danecek, P.; Bonfield, J.K.; Liddle, J.; et al. Twelve years of SAMtools and BCFtools,
412 *GigaScience* 2021, 10, giab008, <https://doi.org/10.1093/gigascience/giab008>.
- 413 42. Garrison, E.; Marth, G. Haplotype-based variant detection from short-read sequencing.
414 *arXiv.org* 2012, <https://arxiv.org/abs/1207.3907>.
- 415 43. Robinson, J.T.; Thorvaldsdottir, H.; Wenger, A.M.; Zehir, A.; Mesirov, J.P. Variant
416 Review with the Integrative Genomics Viewer (IGV). *Cancer Research* 2017, 77, 31-34.
- 417 44. Katoh, K.; Standley, D.M. MAFFT multiple sequence alignment software version 7:
418 improvements in performance and usability. *Mol Biol Evol.* 2013, 30, 772-780.
419 doi:10.1093/molbev/mst010
- 420 45. Altschul, S.F.; Gish, W.; Miller, W.; Myers, EW.; Lipman, D.J. Basic local alignment
421 search tool. *J Mol Biol.* 1990, 215, 403-10. doi: 10.1016/S0022-2836(05)80360-2.
- 422 46. Minh, B.Q.; Schmidt, H.A.; Chernomor, O.; et al. IQ-TREE 2: New Models and
423 Efficient Methods for Phylogenetic Inference in the Genomic Era [published correction

- 424 appears in Mol Biol Evol. 2020 Aug 1;37(8):2461]. Mol Biol Evol. 2020, 37, 1530-
425 1534. doi:10.1093/molbev/msaa015
- 426 47. Letunic, I.; Bork, P. Interactive tree of life (iTOL) v3: an online tool for the display and
427 annotation of phylogenetic and other trees. Nucleic Acids Res. 2016, 44, W242-W245.
428 doi:10.1093/nar/gkw290
- 429 48. Kumar, S.; Stecher, G.; Li, M.; Knyaz, C. Tamura K. MEGA X: Molecular
430 Evolutionary Genetics Analysis across Computing Platforms. Mol Biol Evol. 2018, 35,
431 1547-1549. doi: 10.1093/molbev/msy096.
432
433
434

435

FIGURE LEGEND

436

437 **Figure 1. Schematic representation of the structure of the SARS-CoV-2 genomes**
438 **obtained from the nasopharyngeal samples and from the culture supernatants and of the**
439 **recombination events over time, in reference to parental genomes of the B.1.160 and**
440 **Alpha variants.**

441 a. Genome map and annotation. b. Genome structure and mutations. Blue color of rectangles
442 indicates sequences from a B.1.160 variant; yellow color indicates sequences from an Alpha
443 variant; green color indicates co-detection of sequences from a B.1.160 variant and from an
444 Alpha variant; grey color indicates sequences from indeterminate origin. Signature mutations
445 from the B.1.160 and Alpha variants are indicated by a blue background and a yellow
446 background, respectively. Signature mutations that are absent are indicated by a red font.
447 $\Delta 21765$: -6 nucleotides; $\Delta 21991$: -3 nucleotides. Nsp, nonstructural protein; ORF, open
448 reading frame.

449

450 **Figure 2. Majority nucleotides (a) and nucleotide diversity (b) for sequences obtained**
451 **from the respiratory samples and the culture supernatant at nucleotide positions of the**
452 **SARS-CoV-2 genome that harbor signature mutations of the B.1.160 or Alpha variants.**

453 Nucleotide positions are in reference to the genome of the Wuhan-Hu-1 isolate GenBank
454 accession no. NC_045512.2.

455 a: B.1.160 nucleotides are indicated by a blue background; Alpha nucleotides are indicated by
456 a yellow background. Del, nucleotide deletion

457 b: Nucleotide diversity is the proportion of sequence reads that do not harbor the consensus
458 (majority) nucleotide.

459

460 **Figure 3. Phylogenetic analyses based on SARS-CoV-2 genomes (a) and spike gene**

461 **sequences (b).**

462 Sequences obtained from the case-patient are indicated by a grey background, and those
463 obtained from cultures are underlined. Other sequences from our SARS-CoV-2 sequence
464 database are indicated by a blue font when classified as of the B.1.160 variant, and by a
465 yellow font when classified as of the Alpha variant. Sequences are labeled with their GISAID
466 (<https://www.gisaid.org/>) [34] identifiers. Trees are rooted with the genome of the Wuhan-
467 Hu-1 isolate GenBank accession no. NC_045512.2.

468

469

470

TABLE

471

472 **Table 1.** Genome sequences obtained from the sequential nasopharyngeal samples of the case-
473 patient

474

GISAID identifier	Sampling time post-diagnosis (months)	Next-generation sequencing technology, instrument
EPI_ISL_6332079	M0	Illumina, NovaSeq
EPI_ISL_10816743	Month 8	Illumina, NovaSeq
EPI_ISL_11030507	Month 9	Illumina, NovaSeq
EPI_ISL_10816731	Month 10	Illumina, NovaSeq
EPI_ISL_10816742	Month 11	Nanopore, GridION
EPI_ISL_10816744	Month 13	Illumina, NovaSeq
EPI_ISL_10816733	Month 14	Illumina, NovaSeq

475


476 **Table 2.** Genome sequences obtained from the culture supernatants

477

GISAID identifier	Sampling date of the nasopharyngeal sample	Time to cytopathic effect (days)	Next-generation sequencing technology, instrument
EPI_ISL_10816730	Month 8	8	Illumina, NovaSeq
EPI_ISL_10816732	Month 9	4	Illumina, NovaSeq
EPI_ISL_10816734	Month 11	4	Illumina, NovaSeq
EPI_ISL_10816735	Month 14	5	Illumina, NovaSeq
EPI_ISL_10816738	Month 14	7	Illumina, NovaSeq

478

479

Fig. 1**a. Genome map and annotation****b. Genome structure and mutations**

Parental B.1.160 (Marseille-4) variant genome




Fig. 2

a.

Nucleotide positions	Majority nucleotides														
	Wuhan-Hu-1 isolate genome Signature mutations in B.1.160/Marseille-4 genomes Signature mutations in Alpha genomes			Nasopharyngeal samples						Culture supernatants					
				SARS-CoV-2 diagnosis						SARS-CoV-2 diagnosis					
Month 8	Month 9	Month 10	Month 11	Month 13	Month 14	Month 8	Month 9	Month 11	Month 14	Month 14	Month 8	Month 9	Month 11	Month 14	Month 14
913	C	-	U	-	-	-	U	U	U	U	-	-	U	U	U
3267	C	-	U	-	-	-	U	U	U	-	-	-	U	-	-
4543	C	U	-	U	U	U	U	U	U	U	U	U	U	U	U
5629	G	U	-	U	U	U	U	U	U	U	U	U	U	U	U
5986	C	-	U	-	-	-	-	-	-	-	-	-	U	-	-
9526	G	U	-	U	U	U	U	U	U	U	U	U	U	U	U
11497	C	U	-	U	U	U	U	U	U	U	U	U	U	U	U
13993	G	U	-	U	U	U	U	U	U	U	U	U	U	U	U
15766	G	U	-	U	U	U	U	U	U	U	U	U	U	U	U
16889	A	G	-	G	G	G	G	G	G	G	G	G	G	G	G
17019	G	U	-	U	U	U	U	U	U	U	U	U	U	U	U
18877	C	U	-	U	U	U	U	U	-	U	U	U	-	-	-
21765	U	-	Del	-	-	-	Del	Del	Del	-	-	Del	Del	Del	Del
21766	A	-	Del	-	-	-	Del	Del	Del	-	-	Del	Del	Del	Del
21767	C	-	Del	-	-	-	Del	Del	Del	-	-	Del	Del	Del	Del
21768	A	-	Del	-	-	-	Del	Del	Del	-	-	Del	Del	Del	Del
21769	U	-	Del	-	-	-	Del	Del	Del	-	-	Del	Del	Del	Del
21770	G	-	Del	-	-	-	Del	Del	Del	-	-	Del	Del	Del	Del
21991	U	-	Del	-	-	Del	Del	Del	Del	Del	-	Del	Del	Del	Del
21992	U	-	Del	-	-	Del	Del	Del	Del	Del	-	Del	Del	Del	Del
21993	A	-	Del	-	-	Del	Del	Del	Del	Del	-	Del	Del	Del	Del
22992	G	A	-	A	A	/	-	-	-	-	A	A	-	-	-
23063	A	-	U	-	-	-	U	U	U	U	-	-	U	U	U
23271	C	-	A	-	-	-	A	A	A	A	-	-	A	A	A
23604	C	-	A	-	-	-	A	A	A	A	A	-	A	A	A
23709	C	-	U	-	-	-	U	U	U	U	-	-	U	U	U
24506	U	-	G	-	-	-	G	G	G	G	-	-	G	G	G
24914	G	-	C	-	-	-	C	C	C	C	-	-	C	C	C
25563	G	U	-	U	U	U	-	U	-	-	U	U	U	-	-
25710	C	U	-	U	U	U	-	U	-	-	U	U	U	-	-
26735	C	U	-	U	U	U	-	U	-	-	U	U	U	-	-
26876	U	C	-	C	-	-	C	-	-	-	C	C	C	C	-
28975	G	C	-	C	-	-	C	C	C	C	C	C	C	C	C
28977	C	-	U	-	-	-	-	-	-	-	-	-	-	-	-
29399	G	A	-	A	A	A	A	A	A	A	A	A	A	A	A


b.

SARS-CoV-2 diagnosis	Nucleotide diversity (%)																						
	Nasopharyngeal samples						Culture supernatants																
	Month 8	Month 9	Month 10	Month 11	Month 13	Month 14	Month 8	Month 9	Month 11	Month 14	Month 14	Month 8	Month 9	Month 11	Month 14								
0,0	33,9	26,8	35,9	10,0	0,1	0,1	9,0	0,1	0,1	0,1	0,3	0,0	28,8	23,7	39,3	6,8	0,0	0,0	2,4	0,1	0,2	0,4	0,1
0,1	0,0	0,0	0,0	7,8	0,0	0,1	0,3	0,2	0,2	0,8	0,1	0,3	0,0	0,0	0,0	0,0	0,0	0,0	0,0	0,2	0,2	0,8	0,1
2,8	0,5	1,6	0,2	11,4	0,6	0,0	0,8	1,9	0,9	5,3	1,5	0,0	0,0	0,0	10,3	0,0	0,0	0,0	0,0	18,4	0,0	0,1	
0,0	0,0	0,0	0,0	4,6	0,0	0,0	1,2	0,2	0,2	0,0	0,3	0,1	0,0	0,0	0,0	0,0	0,0	0,0	0,0	0,0	0,0	0,3	
0,1	0,0	0,0	0,0	2,5	0,4	0,0	0,1	0,3	0,2	0,1	0,2	0,4	0,0	0,0	0,0	0,0	0,0	0,0	0,1	0,3	0,2	0,1	0,2
0,1	0,1	0,0	0,1	5,4	0,1	0,0	0,0	0,1	0,0	0,3	0,1	0,1	0,1	0,0	0,0	0,0	0,0	0,0	0,1	0,0	0,3	0,1	
0,1	0,3	0,0	0,1	9,2	0,0	0,0	0,0	0,1	0,0	0,1	0,1	0,1	0,0	0,0	0,0	0,0	0,0	0,0	0,0	0,0	0,1	0,1	
0,1	0,0	0,0	0,0	7,7	0,0	0,2	0,0	0,1	0,0	0,3	0,1	0,0	0,0	0,0	0,0	0,0	0,0	0,0	0,0	0,0	0,3	0,1	
0,0	0,0	0,0	0,0	15,6	0,0	0,0	0,3	0,2	0,4	0,1	0,1	0,0	0,0	0,0	0,0	0,0	0,0	0,0	0,2	0,2	0,4	0,1	0,1
0,0	47,0	0,0	0,0	6,8	0,0	0,1	2,7	0,2	0,0	0,2	0,1	0,1	0,0	0,0	0,0	0,0	0,0	0,0	0,0	0,0	0,2	0,1	
0,1	14,7	11,0	38,3	39,2	22,6	22,9	2,1	0,0	21,8	23,7	21,2	0,0	14,7	11,0	38,3	39,2	22,6	22,9	2,1	0,0	21,8	23,7	21,2
0,0	16,2	11,8	44,0	10,9	1,6	1,1	2,2	0,0	1,2	1,6	1,0	0,0	16,2	11,8	44,0	10,9	1,6	1,1	2,2	0,0	1,2	1,6	1,0
0,1	15,4	11,1	42,8	19,6	0,0	0,0	2,1	0,0	0,0	0,1	0,0	0,1	15,4	11,1	42,8	19,6	0,0	0,0	2,1	0,0	0,0	0,1	0,0
0,0	15,4	11,2	43,1	10,4	0,0	0,0	2,1	0,0	0,0	0,1	0,1	0,0	15,4	11,2	43,1	10,4	0,0	0,0	2,1	0,0	0,0	0,1	0,1
0,0	15,6	11,5	43,7	13,7	0,2	0,2	2,1	0,1	0,2	0,5	0,5	0,0	15,6	11,5	43,7	13,7	0,2	0,2	2,1	0,1	0,2	0,5	0,5
0,1	18,2	15,2	47,6	9,6	5,6	5,6	3,6	0,0	7,2	6,4	6,5	0,0	18,2	15,2	47,6	9,6	5,6	5,6	3,6	0,0	7,2	6,4	6,5
0,0	20,3	17,3	18,6	22,1	1,3	4,3	0,1	2,1	2,5	0,7	1,4	0,0	20,3	17,3	18,6	22,1	1,3	4,3	0,1	2,1	2,5	0,7	1,4
0,1	20,4	16,9	18,1	20,3	1,3	5,6	0,1	2,1	2,5	2,0	2,1	0,1	20,4	16,9	18,1	20,3	1,3	5,6	0,1	2,1	2,5	2,0	2,1
0,1	20,6	16,7	17,7	17,8	3,7	18,9	0,1	11,5	7,4	10,7	12,6	0,1	20,6	16,7	17,7	17,8	3,7	18,9	0,1	11,5	7,4	10,7	12,6
0,3	33,3	/	20,6	4,8	0,0	0,0	5,5	0,1	0,0	0,2	0,3	0,0	33,3	/	20,6	4,8	0,0	0,0	5,5	0,1	0,0	0,2	0,3
0,0	50,0	33,3	27,1	12,4	0,0	0,0	6,7	0,1	0,0	0,4	0,4	0,0	50,0	33,3	27,1	12,4	0,0	0,0	6,7	0,1	0,0	0,4	0,4
0,2	15,7	20,0	44,2	4,2	0,0	0,1	5,1	0,0	0,3	0,2	0,2	0,2	15,7	20,0	44,2	4,2	0,0	0,1	5,1	0,0	0,3	0,2	0,2
0,1	24,8	25,6	37,8	6,0	0,0	0,1	3,5	0,1	0,1	0,1	0,1	0,1	24,8	25,6	37,8	6,0	0,0	0,1	3,5	0,1	0,1	0,1	0,1
0,1	27,5	28,1	37,8	7,8	0,0	0,1	3,5	0,1	0,1	0,1	0,1	0,1	27,5	28,1	37,8	7,8	0,0	0,1	3,5	0,1	0,1	0,1	0,1
0,0	31,2	25,0	31,9	17,7	0,0	0,1	3,2	0,1	0,0	0,1	0,1	0,0	31,2	25,0	31,9	17,7	0,0	0,1	3,2	0,1	0,0	0,1	0,1
0,0	11,6	24,7	43,9	18,7	0,0	0,1	4,4	0,0	0,0	0,2	0,1	0,0	11,6	24,7	43,9	18,7	0,0	0,1	4,4	0,0	0,0	0,2	0,1
0,0	46,2	40,2	20,4	27,4	0,0	0,0	5,6	0,1	0,3	0,2	0,1	0,0	46,2	40,2	20,4	27,4	0,0	0,0	5,6	0,1	0,3	0,2	0,1
0,1	42,2	34,4	17,6	26,0	0,0	0,1	7,4	0,1	0,0	0,3	0,0	0,0	42,2	34,4	17,6	26,0	0,0	0,1	7,4	0,1	0,0	0,3	0,0
0,0	37,9	43,5	9,1	8,6	0,0	19,6	17,0	0,0	0,1	0,3	0,2	0,0	37,9	43,5	9,1	8,6	0,0	19,6	17,0	0,0	0,1	0,3	0,2
0,0	39,2	46,4	12,6	37,2	0,0	22,5	14,7	0,2	0,2	0,2	0,2	0,0	39,2	46,4	12,6	37,2	0,0	22,5	14,7	0,2	0,2	0,2	0,2
0,4	32,8	0,0	0,0	16,6	0,0	5,5	7,3	0,0	0,1	0,1	0,3	0,0	32,8	0,0	0,0	16,6	0,0	5,5	7,3	0,0	0,1	0,1	0,3
0,0	45,1	2,5	0,0	2,8	0,7	0,0	7,3	0,0	0,0	0,2	0,1	0,0	45,1	2,5	0,0	2,8	0,7	0,0	7,3	0,0	0,0	0,2	0,1
0,0	0,1	0,0	0,0	9,3	0,0	0,0	0,0	0,0	0,1	0,1	0,5	0,0	0,1	0,0	0,0	9,3	0,0	0,0	0,0	0,1	0,1	0,5	


Mean	0,2	20,1	14,7	19,8	13,2	1,1	3,1	4,3	0,6	1,9	1,6	1,5
Standard deviation	0,5	16,4	14,3	18,2	8,9	3,9	6,8	6,4	2,0	4,9	4,4	4,1
Median	0,1	18,2	11,6	18,1	10,3	0,0	0,1	2,2	0,1	0,2	0,2	0,2

Fig. 3

a.



b.



1 **SUPPLEMENTARY MATERIAL**

2 **Full-length title:**

3 **Sequential appearance and isolation of a SARS-CoV-2 recombinant between two major**
4 **SARS-CoV-2 variants in a chronically infected immunocompromised patient**

5

6 **SUPPLEMENTARY METHODS**

7 At our institute, SARS-CoV-2 real-time reverse-transcription-PCR (qPCR) was
8 performed on nasopharyngeal samples collected from patients tested by real-time reverse-
9 transcription-PCR (qPCR) using the BGI real-time fluorescent RT-PCR assay (BGI
10 Genomics, Shanghai Fosun Long March Medical Science Co., Ltd., Shenzhen, China) or the
11 NeuMoDx SARS-CoV-2 assay (NeuMoDx Molecular, Ann Arbor, Michigan). Outside our
12 institute (medical biology laboratory Alphabio, hôpital Européen, France), SARS-CoV-2
13 qPCR was performed using the BD MAX System (Becton Dickinson, Sparks, MD, USA).

14

15 **SUPPLEMENTARY RESULTS**

16 ***Virological follow-up by SARS-CoV-2 real-time reverse-transcription-PCR (qPCR)***

17 SARS-CoV-2 qPCR performed on nasopharyngeal samples was positive between
18 summer 2020 (at time of SARS-CoV-2 diagnosis) and Month 4 post-diagnosis, then negative
19 once at Month 5 but positive again on the next sample tested in Month 7. Between Month 8
20 and Month 11, qPCR remained almost always positive being only transiently negative for ≤ 3
21 days. Then qPCR was consistently positive when performed between Month 13 and Month 14
22 post-diagnosis.

23 ***Nucleotide diversity at positions harboring signature mutations of the B.1.160 or Alpha***
24 ***variants***

25 Regarding the SARS-CoV-2 genomes obtained from the respiratory samples, which

26 were obtained with the Illumina technology except for the sample collected at Month 11 post-
27 SARS-CoV-2 diagnosis for which the genome was obtained with the Nanopore technology,
28 nucleotide diversity at the 35 positions harboring signature mutations of the B.1.160 or Alpha
29 variants differed according to the time of sample collection. It was low at time of diagnosis in
30 2020, with a mean (\pm standard deviation) value of $0.2\pm 0.5\%$, increased to reach high values at
31 Month 8 ($20.1\pm 16.4\%$), at Month 9 ($14.7\pm 14.3\%$), at Month 10 ($19.8\pm 18.2\%$), and at Month
32 11 ($13.2\pm 8.9\%$), then decreased to low values again at Month 13 ($1.1\pm 3.9\%$) and at Month 14
33 ($3.1\pm 6.8\%$) (Figure 2 of the main text). The low nucleotide diversity observed for genomes
34 obtained at Month 13 and at Month 14 indicated that the mosaicism consisting in the presence
35 of signature mutations of the two variants was not explained by a co-infection by these two
36 variants or by a contamination of the samples prior or during the next-generation sequencing
37 procedure.

38 Regarding the genomes obtained from the culture supernatants, which were all obtained with
39 the Illumina technology, nucleotide diversity at positions harboring signature mutations of the
40 B.1.160 or Alpha variants was low, indicating that these genomes, including those
41 recombinants, were generated from a single viral isolate. Indeed, mean nucleotide diversity
42 ranged between $0.6\pm 2.0\%$ and $4.3\pm 6.4\%$ (Figure 2 of the main text). The viral genomes
43 obtained from the culture of the respiratory samples collected at Month 14 were highly similar
44 to the viral genome obtained directly from the respiratory sample collected at Month 14.

45 ***Generation of additional sequence reads***

46 Sequencing of reverse-transcription-PCR-targeted regions: We attempted to generate
47 sequence reads that are hybrids of the B.1.160 and Alpha variants from the respiratory sample
48 collected at Month 11 by PCR amplification of the regions overlapping re-combination sites
49 then next-generation sequencing with the Oxford Nanopore Technology (ONT) on a
50 GridION instrument (Oxford Nanopore Technologies Ltd., Oxford, United Kingdom).

51 Amplicons corresponding to positions 3,100-4,570 (in reference to the genome of the Wuhan-
52 Hu-1 isolate GenBank accession no. NC_045512.2) were amplified using the following
53 primers (in 5'-3' orientation): Forward: TTCAACCTGAAGAA-GAGCAA; reverse:
54 TGGCATTGTAACAAGAGTTT. Amplicons corresponding to positions 24,813-29,074
55 were amplified using the following primers: Forward: ATGGAAAAGCACACTTTCCT;
56 reverse: GCTTTAGTGGCAGTACGTTT. For the amplicons corresponding to positions
57 3,100-4,570, 87% of the reads were hybrids harboring both Alpha (C3267U) and B.1.160
58 (C4543U) signature mutations. For the amplicon corresponding to positions 24,813-29,074,
59 70% of the reads were hybrids harboring Alpha (G24914C) and B.1.160 (G25563U,
60 C25710U, C26735U, U26876C and G28975C) mutations, and 24% were hybrids harboring
61 Alpha mutation G24914C and B.1.160 mutation G28975C.

62 Metagenomic sequencing: Next-generation sequencing was also carried out using a
63 metagenomic approach with the Nanopore technology on a GridION instrument (Oxford
64 Nanopore Technologies Ltd.) to attempt obtaining long sequence reads and detect additional
65 reads that are hybrids of the B.1.160 and Alpha variants. For the first recombination site, four
66 reads with a length ranging between 1,855-11,979 nucleotides were obtained, which harbored
67 signature mutations of the Alpha (C3267U) and B.1.160 (C4543U) variants. For the third
68 recombination site, four reads with a length comprised between 1,486-8,143 nucleotides were
69 obtained that harbored signature mutations of the Alpha (G24914C) and B.1.160 (C25563U)
70 variants.

71 ***Viral culture***

72 Cytopathic effects were observed between 4 and 8 days after the inoculation of the
73 nasopharyngeal samples on Vero E6 cells as previously described [1] (Table 2 of the main
74 text).

75 ***Phylogenetic analyses based on SARS-CoV-2 genomes and spike gene sequences***

76 Phylogeny reconstructions were performed based on viral genomes or spike genes,
77 which included sequences obtained directly from the nasopharyngeal samples and from the
78 cultures, and their best BLAST hits from the IHU Méditerranée Infection sequence database
79 that were classified as B.1.160 or Alpha variants [2]. The genome obtained from the
80 nasopharyngeal sample collected in 2020 at time of SARS-CoV-2 diagnosis was clustered
81 with genomes of the B.1.160 variant, apart from the other genomes obtained from the case-
82 patient (Figure 3a of the main text). Other genomes obtained from the nasopharyngeal
83 samples collected since Month 8 and those obtained from cultures of the nasopharyngeal
84 samples collected since Month 8 were also clustered with genomes of the B.1.160 variant, but
85 they were clustered together, apart from the other genomes. The Alpha variant genomes were
86 clustered apart from all other genomes. Spike gene phylogeny showed the clusterisation with
87 sequences of the B.1.160 variant of the sequences obtained from the case-patient either
88 directly or post-culture from samples collected between SARS-CoV-2 diagnosis and Month 9
89 post-diagnosis (Figure 3b of the main text). In contrast, sequences obtained from the case-
90 patient either directly or post-culture from samples collected since Month 10 post-diagnosis
91 were clustered with Alpha variant sequences.

92

93 **SUPPLEMENTARY FIGURES**

94 **Supplementary Figure S1. Majority nucleotides and nucleotide diversity for sequences**
95 **obtained from the respiratory samples and the culture supernatant at nucleotide**
96 **positions of the SARS-CoV-2 genome that harbor signature mutations of the B.1.160 or**
97 **Alpha variants and at any other positions that harbor mutations.**

98 Nucleotide positions are in reference to the genome of the Wuhan-Hu-1 isolate GenBank
99 accession no. NC_045512.2. B.1.160 nucleotides are indicated by a blue background; Alpha
100 nucleotides are indicated by a yellow background. Del, nucleotide deletion. Nucleotide

107 **SUPPLEMENTARY TABLES**

108

109 **Supplementary Table S1. List of GISAID identifiers for sequences used in the present**

110 **study.**

111 All genomes analyzed here were obtained in our laboratory (University hospital institute

112 Méditerranée Infection, Marseille, France). The GISAID sequence database is accessible at:

113 (<https://www.gisaid.org/>) [3].

Source sample	GISAID identifier
Respiratory samples	EPI_ISL_10816729
	EPI_ISL_10816731
	EPI_ISL_10816733
	EPI_ISL_10816740
	EPI_ISL_10816742
	EPI_ISL_10816743
	EPI_ISL_10816744
	EPI_ISL_11030507
	EPI_ISL_2757096
	EPI_ISL_3054898
	EPI_ISL_3054899
	EPI_ISL_3055037
	EPI_ISL_3055223
	EPI_ISL_3055225
	EPI_ISL_3055227
	EPI_ISL_3055234
	EPI_ISL_3055235
	EPI_ISL_3830105
	EPI_ISL_3830215
	EPI_ISL_3831874
	EPI_ISL_3933559
	EPI_ISL_3933565
	EPI_ISL_3933569
	EPI_ISL_3933571
	EPI_ISL_3933572
	EPI_ISL_3934656
	EPI_ISL_3934682
	EPI_ISL_3934683
	EPI_ISL_4394365

114

115
116 *Supplementary Table S1 - continued*

EPI_ISL_4944362
EPI_ISL_4944364
EPI_ISL_4951784
EPI_ISL_4951785
EPI_ISL_6332079
EPI_ISL_6737742
EPI_ISL_7376142
EPI_ISL_7376355
EPI_ISL_8321213
EPI_ISL_8321223
EPI_ISL_8321228
EPI_ISL_8321229
EPI_ISL_8321241
EPI_ISL_8321242
EPI_ISL_8321256
EPI_ISL_8709907
EPI_ISL_8709910
EPI_ISL_8711731
EPI_ISL_9773781
EPI_ISL_9774389
EPI_ISL_9774894
EPI_ISL_9774895

Culture supernatants

EPI_ISL_10816730
EPI_ISL_10816732
EPI_ISL_10816734
EPI_ISL_10816735
EPI_ISL_10816738

117

118 **References**

- 119 1. La Scola, B.; Le Bideau, M.; Andreani, J.; et al. Viral RNA load as determined by cell
120 culture as a management tool for discharge of SARS-CoV-2 patients from infectious
121 disease wards. *Eur J Clin Microbiol Infect Dis.* **2020**, *39*, 1059-1061.
- 122 2. Colson, P.; Fournier, PE.; Chaudet, H.; et al. Analysis of SARS-CoV-2 Variants From
123 24,181 Patients Exemplifies the Role of Globalization and Zoonosis in Pandemics. *Front*
124 *Microbiol.* **2022**, *12*, 786233. doi: 10.3389/fmicb.2021.786233.

- 125 3. Alm, E.; Broberg, EK.; Connor, T.; et al. Geographical and temporal distribution of
126 SARS-CoV-2 clades in the WHO European Region, January to June 2020. *Euro Surveill.*
127 **2020**, 25, 2001410.

128

129